Literature DB >> 32813019

Distant Metastasis in Pediatric and Adolescent Differentiated Thyroid Cancer: Clinical Outcomes and Risk Factor Analyses.

Kiminori Sugino1, Mitsuji Nagahama1, Wataru Kitagawa1, Keiko Ohkuwa1, Takashi Uruno1, Kenichi Matsuzu1, Akifumi Suzuki1, Chisato Tomoda1, Kiyomi Yamada Hames1, Junko Akaishi1, Chie Masaki1, Koichi Ito1.   

Abstract

CONTEXT: The specific characteristics of pediatric and adolescent differentiated thyroid cancer (DTC) is the more frequent occurrence of distant metastasis (DM) compared with adult DTC.
OBJECTIVE: To investigate the clinical outcomes of DM in this population and analyze risk factors related to DM. DESIGN, SETTING, AND PARTICIPANTS: Medical records of 171 patients with DTC < 19 years old, who underwent initial surgery between 1979 and 2014 were retrospectively reviewed. MAIN OUTCOME MEASURE: Clinical responses to radioiodine (RAI) therapy evaluated by the American Thyroid Association (ATA) guidelines for adult DTC and Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Risk factors related to distant-metastasis-free survival (DMFS).
RESULTS: DM was observed in 29 patients, and all were lung metastases. The pattern of lung metastasis was classified into 3 categories: macronodular, micronodular, and no apparent nodule (detected only by RAI scintigraphy). Patients with excellent responses according to the ATA guideline criteria or complete remission of the RECIST criteria were most frequently observed in those with no apparent nodule. Significant factors related to DMFS were sex, clinical lymph node metastasis (LNM), extrathyroidal extension, and number of LNM. Subjects were divided into 3 groups according to the number of risk factors: low risk (no risk factors); intermediate risk (1 risk factor); and high risk (≥2 risk factors). Twenty-year DMFS rates in the low-, intermediate-, and high-risk groups were 99.0%, 71.7%, and 28.6%, respectively.
CONCLUSION: To achieve the full efficacy of RAI therapy, early diagnosis of DM before apparent metastases appear is desirable. The selective approach would be preferable for pediatric and adolescent DTC. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  distant metastasis; pediatric differentiated thyroid cancer; risk stratification

Year:  2020        PMID: 32813019     DOI: 10.1210/clinem/dgaa545

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Can Cervical Lymph Node Metastasis Increase the Risk of Distant Metastasis in Papillary Thyroid Carcinoma?

Authors:  Wenlong Wang; Ying Ding; Wei Jiang; Xinying Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-24       Impact factor: 6.055

2.  Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer.

Authors:  Aime T Franco; Julio C Ricarte-Filho; Theodore W Laetsch; Andrew J Bauer
Journal:  J Clin Invest       Date:  2021-09-15       Impact factor: 19.456

3.  Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma.

Authors:  Adam Stenman; Samuel Backman; Klara Johansson; Johan O Paulsson; Peter Stålberg; Jan Zedenius; C Christofer Juhlin
Journal:  Endocr Relat Cancer       Date:  2021-04-29       Impact factor: 5.678

4.  High Incidence of Distant Metastasis Is Associated With Histopathological Subtype of Pediatric Papillary Thyroid Cancer - a Retrospective Analysis Based on SEER.

Authors:  Xue Zeng; Zhihong Wang; Zhiqiang Gui; Jingzhe Xiang; Mengsu Cao; Wei Sun; Liang He; Wenwu Dong; Jiapeng Huang; Dalin Zhang; Chengzhou Lv; Ting Zhang; Liang Shao; Ping Zhang; Hao Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-11       Impact factor: 5.555

5.  Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion-Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?

Authors:  Steven G Waguespack; Sanjit O Tewari; Naifa L Busaidy; Mark E Zafereo
Journal:  JCO Precis Oncol       Date:  2022-04

Review 6.  Strategies for Radioiodine Treatment: What's New.

Authors:  Clotilde Sparano; Sophie Moog; Julien Hadoux; Corinne Dupuy; Abir Al Ghuzlan; Ingrid Breuskin; Joanne Guerlain; Dana Hartl; Eric Baudin; Livia Lamartina
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

7.  A Predictive Model for the 10-year Overall Survival Status of Patients With Distant Metastases From Differentiated Thyroid Cancer Using XGBoost Algorithm-A Population-Based Analysis.

Authors:  Shuai Jin; Xing Yang; Quliang Zhong; Xiangmei Liu; Tao Zheng; Lingyan Zhu; Jingyuan Yang
Journal:  Front Genet       Date:  2022-07-08       Impact factor: 4.772

8.  Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape.

Authors:  Marloes Nies; Rena Vassilopoulou-Sellin; Roland L Bassett; Sireesha Yedururi; Mark E Zafereo; Maria E Cabanillas; Steven I Sherman; Thera P Links; Steven G Waguespack
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

Review 9.  Radiomics in Differentiated Thyroid Cancer and Nodules: Explorations, Application, and Limitations.

Authors:  Yuan Cao; Xiao Zhong; Wei Diao; Jingshi Mu; Yue Cheng; Zhiyun Jia
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

10.  The Role of m6A RNA Methylation-Related lncRNAs in the Prognosis and Tumor Immune Microenvironment of Papillary Thyroid Carcinoma.

Authors:  Wenlong Wang; Cong Shen; Yunzhe Zhao; Botao Sun; Xiangyuan Qiu; Shujuan Yin; Jiaxin Chen; Xinying Li
Journal:  Front Cell Dev Biol       Date:  2022-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.